Phase 2 trial in 196 adults with uncontrolled moderate-to-severe asthma: rilzabrutinib did not significantly reduce loss-of-asthma-control events vs placebo (800 mg/day 38% vs 50%, p=0.29; 1200 mg/day 19% vs 29%, p=0.21). Secondary: asthma control improved.
RCTn = 196
Maspero et al. Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study